NTLA Latest Headlines

FDA draft guidance aims to speed personalized gene therapies for rare diseases

at seekingalpha.com (Thu, 29-Oct 3:52 PM)

Intellia names Jing L. Marantz as CMO as it targets Phase 3 execution and a first in vivo product launch

Market Chameleon (Tue, 13-Oct 11:26 AM)

Intellia uses inducement RSUs to add eight new hires under Nasdaq Rule 5635(c)(4)

Market Chameleon (Mon, 5-Oct 7:31 AM)

Intellia Therapeutics Issues 38,200 RSUs as Inducement Grants to New Hires—What Does This Signal for NTLA’s Growth Ambitions?

Market Chameleon (Mon, 10-Aug 7:55 AM)

Intellia's Positive Phase 3 Data and Strong Cash Position Highlight Road to 2027 Launch

Market Chameleon (Thu, 6-Aug 7:20 AM)